





Innovation happens naturally,
ask Basic Pharma

chemelot

The chemical innovation community


Innovation happens naturally, ask Basic Pharma

The Basic Pharma Group is an independent pharmaceutical company that develops, produces and registers medicines. The holding comprises three business units. Basic Pharma Technologies is responsible for product development, Interdos Pharma is the consultancy branch that looks after the registration of medicines, among other things, and Basic Pharma Manufacturing is the producer of liquid and semisolid preparations. Since establishment in 2003 the organization has followed an impressive growth path in which the move to Chemelot in 2007 is a logical step. "Our business units work intensively together. Step outside and a world of knowledge and learning is available. The same sphere of open innovation and shared know-how is perceptible in Chemelot," explains Basic Pharma CEO Bob Kool. This makes Chemelot an environment in which Basic Pharma really thrives.



Pharmaceuticals, developed and manufactured here

At Chemelot, Basic Pharma has found the space to give further shape to its ambitions. From the original idea to commercial medicine, a large part of the task is carried out in-house. Help with specific challenges is obtained from an extensive international network or the neighbors in Sittard. Bob Kool: "We are surrounded on this campus by companies that are active in material sciences and life sciences. Customers, partners and suppliers are right on our doorstep, which is a great advantage. For example, we order specialist analytical work from a specialist laboratory on site." Basic Pharma is an enthusiastic supporter of a growing Chemelot, with a mild preference for a certain type of company. "Biotechnology. Because that offers possibilities of forming strategic alliances and developing products together. We can participate in these alliances via our venture capital company Limburg Ventures. The more companies come to Chemelot, the more added value. We are open to this."






Best in class, acknowledged globally

In March 2003, the Basic Pharma Group was established as an independent company based on an existing production area in Roermond. Research & development were started and a quality control laboratory opened its doors. In 2004, Basic Pharma joined forces with Interdos Pharma and the present form of organization came about, in which specialisms were placed in business units. In 2007, the company grew too big for the Roermond site and moved to the Chemelot Research & Business Campus in Geleen. Activities include the development of study medication, regulatory affairs, pharmacovigilance, registration dossiers, package leaflet tests, GMP and ISO quality systems and clinical studies. This is only a part of the whole package that Basic Pharma currently offers its international circle of customers.



Trusted by the best

Basic Pharma produces medicines in its own facility. But the emphasis lies on the development of medicines and formulae that are licensed. "The last thing we want is to get in our customers' way," is how Bob Kool explains this strategic choice. Products are born from an R&D process or developed from a patent to then find their way to a suitable marketing and sales organization. This will happen in the shorter or longer term and, depending on the need, will be supported by the specialist knowledge of Inter-dos Pharma, so that a bridge can be successfully built between science and commerce.



Basic Pharma is now working on...

As Basic Pharma licenses many medicines, innovation and development are on the agenda. We are currently turning to a new generation of products. Besides product development, the focus lies on sterile preparations. New, state-of-the-art clean rooms are being built for this in which pharmaceutical products are prepared in sterile conditions. These facilities are also available to third parties. The Healthcare Inspectorate has issued the GMP certificate, underlining the fact that the new Basic Pharma complex has everything available in-house and can look confidently forward to a successful and flourishing future.





chemelot